Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44266   clinical trials with a EudraCT protocol, of which   7347   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-003884-71
    Sponsor's Protocol Code Number:LPS13649
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-10-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2013-003884-71
    A.3Full title of the trial
    A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)
    Studio di follow-up a lungo termine, di fase IIIB-IV per pazienti che hanno partecipato allo studio CAMMS03409
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase IIIB-IV long term follow-up study for patients who participated in CAMMS03409
    Studio di follow-up a lungo termine, di fase IIIB-IV per pazienti che hanno partecipato allo studio CAMMS03409
    A.3.2Name or abbreviated title of the trial where available
    TOPAZ
    A.4.1Sponsor's protocol code numberLPS13649
    A.5.3WHO Universal Trial Reference Number (UTRN)U1111-1148-2987
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGenzyme Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGenzyme Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSANOFI S.P.A.
    B.5.2Functional name of contact pointCONTACT POINT
    B.5.3 Address:
    B.5.3.1Street AddressVIALE BODIO, 37/B
    B.5.3.2Town/ cityMILANO
    B.5.3.3Post code20158
    B.5.3.4CountryItaly
    B.5.4Telephone number+39800226343
    B.5.5Fax number+390239394168
    B.5.6E-mailinformazioni.medicoscientifiche@sanofi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Lemtrada
    D.2.1.1.2Name of the Marketing Authorisation holderGenzyme Therapeutics Ltd.
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLemtrada
    D.3.2Product code GZ402673
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNalemtuzumab
    D.3.9.1CAS number 216503-57-0
    D.3.9.2Current sponsor codeGZ402673
    D.3.9.4EV Substance CodeSUB12459MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeHumanised Monoclonal Antibody
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsing-remitting multiple sclerosis
    Sclerosi Multipla recidivante-remittente
    E.1.1.1Medical condition in easily understood language
    Relapsing-remitting multiple sclerosis
    Sclerosi Multipla recidivante-remittente
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.1
    E.1.2Level PT
    E.1.2Classification code 10063399
    E.1.2Term Relapsing-remitting multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate long-term safety of alemtuzumab
    Valutare la sicurezza a lungo termine di alemtuzumab
    E.2.2Secondary objectives of the trial
    - To evaluate long term efficacy of alemtuzumab
    - To evaluate the safety profile of patients who received other Disease Modifying Treatment's (DMT) following alemtuzumab treatment
    - To evaluate patient-reported Quality of Life (QoL) outcomes and health resource utilization of patients who received alemtuzumab
    - To evaluate as needed re-treatment with alemtuzumab and other DMTs
    - Valutare l’efficacia a lungo termine di alemtuzumab
    - Valutare il profilo di sicurezza in pazienti sottoposti ad altre terapie che modificano l’andamento della malattia (DMT) dopo il trattamento con alemtuzumab
    - Valutare gli esiti riferiti dai pazienti di Qualità della Vita (QoL) e dell’utilizzo di risorse di sanitarie da parte dei pazienti trattati con alemtuzumab
    - valutare, se necessario, il ritrattamento con alemtuzumab e con altri DMT
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Patient has completed at least 48 months of the Extension Study CAMMS03409
    - Signed written informed consent form
    - Pazienti che abbiano completato almeno 48 mesi dello studio di estensione CAMMS03409
    - Modulo di consenso informato scritto firmato (ICF)
    E.4Principal exclusion criteria
    - Patient participating in another investigational interventional study
    pazienti che stiano partecipando ad un altro studio sperimentale interventistico
    E.5 End points
    E.5.1Primary end point(s)
    - Incidence, duration, grade/intensity, relationship to study drug, and outcome of the following: Serious Adverse Events; Adverse Events
    - Incidence, nature, seriousness, grade/intensity, relationship to study drug, and outcome of the following adverse events of special interest: Specific autoimmune mediated conditions, Infusion-associated reactions, Malignancy, Infections
    - Changes in laboratory parameters
    - Incidenza, durata, grado/intensità, correlazione con il farmaco dello studio ed esito di: Eventi Avversi Gravi (SAE); Eventi Avversi (AE)
    - Incidenza, natura, serietà, grado/intensità, correlazione con il farmaco dello studio ed esito dei seguenti eventi avversi di particolare interesse (AESI): malattie autoimmuni mediate specifiche, reazioni associate all’infusione (IAR), neoplasie, infezioni.
    - Alterazioni dei parametri di laboratorio
    E.5.1.1Timepoint(s) of evaluation of this end point
    Final analysis at study completion (Up to a maximum of 5.5 years). Yearly interim analysis.
    Analisi finali al completamento dello studio (fino ad un massimo di 5.5 anni). Analisi ad interim annuale.
    E.5.2Secondary end point(s)
    - Annualized relapse rate (ARR)
    - Proportion of participants relapse free
    - Change over time in Expanded Disability Status Scale (EDSS) scores
    - Change over time in brain imaging findings
    - Change over time in self-reported quality of life (QoL) as assessed by the Medical Outcome Study (MOS) 36-Item Short-Form Health Survey (SF-36) Version 2
    - Change over time in the Functional Assessment of Multiple Sclerosis (FAMS)
    - Change over time in the EuroQoL in 5 Dimensions (EQ-5D)
    - Pharmaco-economic evaluation (Modified Health Resources Utilization Questionnaire (HRUQ) / Health Related Productivity Questionnaire (HRPQ))
    - Tasso annualizzato di recidive (ARR)
    - percentuale di pazienti senza recidive
    - Variazione nel tempo dei punteggi EDSS (Expanded Disability Status Scale)
    - Variazione nel tempo delle evidenze delle immagini cerebrali
    - Cambiamenti nel tempo della qualità della vita (QoL) autoriportata, valutata mediante questionario Medial Outcome Study (MOS) 36-item Short-form Health Survey (SF-36) Versione 2
    - Cambiamento nel tempo del punteggio FAMS (Functional Assessment of Multiple Sclerosis)
    - Cambiamento nel tempo del punteggio EuroQoL a 5 dimensioni (EQ-5D)
    - Valutazione farmaco-economica (questionario sull’uso delle risorse sanitarie modificato (HRUQ) / Questionario di produttività correlata alla salute (HRPQ)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Final analysis at study completion (Up to a maximum of 5.5 years). Yearly interim analysis.
    Analisi finali al completamento dello studio (fino ad un massimo di 5.5 anni). Analisi ad interim annuale.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA52
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Belgium
    Brazil
    Canada
    Croatia
    Czech Republic
    Denmark
    France
    Germany
    Israel
    Italy
    Mexico
    Netherlands
    Poland
    Russian Federation
    Serbia
    Spain
    Sweden
    Ukraine
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months6
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 799
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2014-10-28. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women Yes
    F.3.3.4Nursing women Yes
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    In case of treatment, cautionary measures from approved labelling or IB are applied
    in caso di trattamento con cicli aggiuntivi di alemtuzumab, il paziente sarà seguito in base alle sp
    F.4 Planned number of subjects to be included
    F.4.1In the member state13
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 399
    F.4.2.2In the whole clinical trial 799
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will be followed for 48-months after the last infusion of alemtuzumab received in the current trial setting. If the 48-month period of safety follow-up continues after the study ends, the patient will be followed by their physician in a regular healthcare setting, in line with the local approved Risk Minimization Plan for alemtuzumab, until the 48-month period is completed.
    i pazienti saranno seguiti per 48 mesi dopo l’ultima infusione di Alemtuzumab ricevuto nell’ambito dello studio clinico. Se il periodo di follow-up di 48 mesi dovesse continuare dopo la fine dello studio, il paziente sarà seguito dal proprio medico come da normale pratica clinica, in linea con il piano di controllo dei rischi per Alemtuzumab fino a quando il periodo dei 48 mesi sarà completato.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-12-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-10-23
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA